Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
C4 Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in Greater China for NSCLC&#59; U.S. IND Cleared"
07/25/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
07/07/2023 SC 13G/A BlackRock Inc. reports a 4.3% stake in C4 Therapeutics, Inc.
06/12/2023 SC 13G/A ArrowMark Colorado Holdings LLC reports a 3% stake in C4 Therapeutics, Inc.
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
Docs: "C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights Preclinical Data Presented at AACR Demonstrated CFT1946 is a Potent and Mutant-Selective BRAF V600 BiDAC™ Degrader&#59; Phase 1/2 Clinical Trial Enrolling Patients"
05/04/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/18/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/14/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/23/2023 8-K/A Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights Phase 1 Dose Escalation Data from the Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Expected in 2H 2023"
02/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/23/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
02/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights Phase 1 Dose Escalation Data from the Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Expected in 2H 2023"
02/14/2023 SC 13G ArrowMark Colorado Holdings LLC reports a 11.8% stake in C4 Therapeutics, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/08/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/02/2023 8-K Quarterly results
01/31/2023 SC 13G/A BlackRock Inc. reports a 7.4% stake in C4 Therapeutics, Inc.
01/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines Phase 1/2 Trial of CFT7455, an IKZF1/3 MonoDAC™ Degrader, Continues to Progress with Phase 1 Dose Escalation Data Expected in 2H 2023&#59; Enrollment Open for Arm Evaluating CFT7455 in Combination with Dexamethasone"
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
Docs: "C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights"
09/22/2022 8-K/A Submission of Matters to a Vote of Security Holders  Interactive Data
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 8-K Quarterly results
08/02/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
06/17/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/17/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy